

Digital Therapeutics

Global Leader



About Us

DarioHealth Corp. (NASDAQ: DRIO) is a leading **Global Digital Therapeutics (DTx)** company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering **evidence-based interventions** that are driven by data, high quality software and coaching, we developed a novel approach that empowers individuals to adjust their lifestyle in a personalized way.

Our Solution

Other companies build their offering around a device, and then cobble together a basic web interface and add generic coaching. Not Dario.

Our evidence-based **digital therapeutic** interventions put the user at the center with sophisticated software, tailored coaching and personal support. This approach offers users a unique and highly personalized experience that results in greater engagement and improved clinical outcomes.


This experience goes beyond the basics of chronic condition management of the traditional healthcare industry.



Billings Growth* (In Millions of \$)

- Revenue
- Deferred

- Membership Model Drives Recurring Revenue
- Multiple channels enable growth acceleration from B2C and B2B



* See appendix 1

DarioHealth Mission Statement

DarioHealth pioneers a personalized, digital user experience, refined and proven to fully engage people to make healthier choices and live life on their terms.



- NPS 77+
- ★ 4.8
- ★ 4.3
- amazon ★ 5

I feel good about my weekly calls with my specialist. I've been more responsible with her calling me every week. It gives me a better sense of what I need to do.

I recommend it to other people too because it's so compact and I don't have to carry around that bulky case, which I never did, and this is the size of an old Bic lighter.

Of the components of the Dario system, when you put them together, it gives you the total picture so that you can control the disease and that the disease doesn't control you.

Growing Industry

Well Positioned To Support Growth



Investment Highlights



Executive Team & Board Members

 Olivier Jarry President & CCO	 Dror Bacher COO	 Allen Kamer Board Member	 Erez Raphael CEO Digital Health Entrepreneur
 João Mendes-Roter VP Marketing	 Professor Itamar Raz Medical Director	 Glen Moller CEO at BehaveCare, Inc	 Zvi Ben-david CFO
 Yoav Shaked Chairman venture capitalis	 Michal Hershkovitz VP Clinical & Regulatory	 Limor Drezner Head of HR	 Yael Lipskin-Moshe Director of Product
			 Yinon Amir Head of Software



Global Reach:

Operates in 6 countries
*USA Leading Region



ROI:

\$165 Average Per Month
*Proved by A1C reduction



Fast Growing Sales:

2017 – \$5.2M
2018 – \$8.1



Safety & Effectiveness:

Cleared by 4 Regulation bodies
including the FDA, TGA,
CE and Health Canada

Appendix 1. - Non-GAAP Financial Measures

We have provided in this presentation financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below. Billings (non-GAAP). We define billings as revenue recognized in accordance with GAAP plus the change in deferred revenue from the beginning to the end of the period and adjustment to the deferred revenue balance due to adoption of the new revenue recognition standard less any deferred revenue balances acquired from business combination(s) during the period. We consider billings to be a useful metric for management and investors because billings drive future revenue, which is an important indicator of the health and viability of our business. There are a number of limitations related to the use of billings instead of GAAP revenue. First, billings include amounts that have not yet been recognized as revenue and are impacted by the term of security and support agreements. Second, we may calculate billings in a manner that is different from peer companies that report similar financial measures. Management accounts for these limitations by providing specific information regarding GAAP revenue and evaluating billings together with GAAP revenue.

Reconciliation of Revenue to Billing (Non-GAAP) U.S. dollars in thousands

	Year Ended December 31		Three Months Ended December 31	
	2018	2017	2018	2017
GAAP Revenue	7,394	5,170	1,700	1,578
Add:				
Change in deferred revenue	736	-	351	-
Billing (Non-GAAP)	8,130	5,170	2,051	1,578